secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2025-03-11T23:59:59+00:00
Accession:  0001104659-25-022435
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Novavax terminates Canada COVID vaccine APA, to recognize $576M revenue in Q1 2025
--------------------------------------------------------------------------------

- Canada terminated APA effective March 7, 2025, citing Novavax's failure to obtain regulatory approval for vaccine from Biologics Manufacturing Centre by Dec 31, 2024.
- Novavax expects to recognize $576M previously in deferred revenue and other liabilities as product revenue in Q1 2025.
- $28M in advance payments must be refunded to Canada within 30 days of the termination notice.
- $20M escrow related to an MOU may be released to Novavax as the MOU is no longer feasible.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000110465925022435/0001104659-25-022435-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000110465925022435/tm258808d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-022435

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer